NGM · Biotechnology

Bicara Therapeutics Inc. (BCAX) Stock

$17.50 +1.39% NGM: BCAX Healthcare

Valuation

MetricValue
Price$17.50
Market Cap$1.15B
P/E Ratio-6.02
P/B Ratio2.70
P/S Ratio0.00
EPS (TTM)$0.00
52-Week High$30.99
52-Week Low$13.70
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-41.49%
ROA-36.19%
ROCE-43.09%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.00
Current Ratio13.85

Annual Financials (USD)

Metric2022202320242025
Revenue$0$0$0$0
Operating Profit$-38.0M$-40.0M$-82.0M$-156.0M
Net Profit$-38.0M$-52.0M$-68.0M$-138.0M
EPS$-0.73$-1.00$-1.25$-2.52
Op Margin————

Balance Sheet (USD)

Metric2022202320242025
Total Assets$7.0M$234.0M$569.0M$431.0M
Total Liabilities$24.0M$15.0M$77.0M$30.0M
Cash$4.0M$230.0M$490.0M$97.0M
Borrowings$0$1.0M$1.0M$2.0M

Latest News

Bicara Therapeutics Insider Sold Shares Worth $833,129, According to a Recent SEC Filing MT Newswires · Jul 10, 2026 Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire · Jul 2, 2026 What Does the Bicara Therapeutics CEO's Sale of 15,000 Shares Mean for Investors? Motley Fool · Jun 13, 2026 Bicara (BCAX) Q4 2025 Earnings Transcript Motley Fool · Jun 1, 2026 Bicara Therapeutics ASCO Data Bolster Ficerafusp Alfa in Head and Neck Cancer MarketBeat · May 22, 2026

Cash Flow (USD)

Metric2022202320242025
Operating Cash Flow$-32.0M$-46.0M$-75.0M$-107.0M
Investing Cash Flow$0$-1.0M$0$-319.0M
Financing Cash Flow$0$0$2.0M$0
Net Cash Flow$-1.0M$226.0M$259.0M$-393.0M
Free Cash Flow$-32.0M$-46.0M$-75.0M$-107.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.14
EV / EBITDA-6.13
FCF Yield-11.03%
Quick Ratio11.59
Interest Coverage0.00
Return 1Y135.20%
Return 3Y—
Return 5Y—

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
CBIOCrescent Biopharma, Inc. $14.91 +5.59% -1.84 $553.82M 0.00%
CGEMCullinan Therapeutics, Inc. $15.53 +0.45% -4.60 $954.44M 0.00%
CMPXCompass Therapeutics, Inc. $0.99 +0.98% -2.06 $178.83M 0.00%
CNTXContext Therapeutics Inc. $0.30 +1.74% -0.64 $27.95M 0.00%
MGNXMacroGenics, Inc. $3.74 +5.35% -16.25 $237.73M 0.00%

About Bicara Therapeutics Inc.

Bicara Therapeutics Inc. is led by CEO Claire Mazumdar Clemon, employs 55 people, headquartered in US, publicly traded since 2024.

Bicara Therapeutics Inc. (BCAX) stock trades at $17.50 with a market capitalization of $1.15B. The stock is valued at a price-to-earnings (P/E) ratio of -6.02, price-to-book of 2.70, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $13.70 and $30.99, and currently trades 43.5% below its 52-week high.

On profitability, Bicara Therapeutics Inc. generates a return on equity (ROE) of -41.49%, return on capital employed of -43.09%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1179.27 +0.83% JNJ Johnson & Johnson $261.44 +1.93% ABBV AbbVie Inc. $276.47 +1.49% MRK Merck & Company, Inc. Common Stock (new) $145.60 +2.26% UNH UnitedHealth Group Incorporated Common Stock (DE) $379.30 +2.25% NVS Novartis AG $143.75 +0.45% AZN AstraZeneca PLC $159.31 +0.33% TMO Thermo Fisher Scientific Inc $658.02 +0.93% AMGN Amgen Inc. $414.87 +1.82% GILD Gilead Sciences, Inc. $151.17 +2.77% ABT Abbott Laboratories $99.60 +1.13% NVO Novo Nordisk A/S $38.64 +1.20%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksAll stock screens
Run Stock Screener Investing Guides